B vitamins for the prevention of vascular disease: Insufficient evidence to justify treatment

JAMA

Volumn 298, Issue 10, 2007, Pages 1212-1214

  Baigent, Colin ^a,b   Clarke, Robert ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Richard Doll Bldg   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; EVIDENCE BASED MEDICINE; HOMOCYSTINURIA; HUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; NOTE;

HOMOCYSTEINE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES; VITAMIN B COMPLEX;

EID: 34548545096     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.10.1212     Document Type: Editorial

References (16)

1. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2(4):386-389.
2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049-1057.
3. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of the published epidemiological studies. J Cardiovasc Risk. 1998;5(4):229-232.
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288(16):2015-2022.
5. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023-2031.
6. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.
7. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.
8. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365(9455):224-232.
9. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ. 2006;333(7578):1114-1117.
10. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation. 2002;106(1)(suppl II):2-741.
11. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA. 2004;291(5):565-575.
12. Bønaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
13. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-1577.
14. Jamison RL, Hartigan P, Kaufman JS, et al; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298(10):1163-1170.
15. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296(22):2720-2726.
16. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151(2):282-287.